Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016


  • Products Id :- GDHC3734CTIDB
  • |
  • Pages: 1665
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 28

Prominent Drugs 30

Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 31

Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma 31

Sep 09, 2016: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level 31

Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma 31

Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans 34

Aug 25, 2016: Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine 34

Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV's APO010 Study 35

Jul 25, 2016: Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma 36

Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 37

Jul 07, 2016: Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio 37

Clinical Trial Profile Snapshots 38

Appendix 1662

Abbreviations 1662

Definitions 1662

Research Methodology 1663

Secondary Research 1663

About GlobalData 1664

Contact Us 1664

Disclaimer 1664

Source 1665

List of Figures

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

GlobalData Methodology 1663

List of Tables

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Celgene Corporation

Johnson & Johnson

Takeda Pharmaceutical Company Limited

Novartis AG

Amgen Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Sanofi

Merck & Co., Inc.

AbbVie Inc

select a license
Single User License
USD 2500 INR 179475
Site License
USD 5000 INR 358950
Corporate User License
USD 7500 INR 538425

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com